News Two more biotechs, Metsera and Maze, cross IPO finish line Metsera and Maze Therapeutics have become the second and third biotechs to complete an IPO on the Nasdaq this year.
News Veru shares plunge despite positive data in obesity trial Veru's obesity candidate achieved the objective of preserving muscle in people taking weight-loss drug Wegovy, but its share price still fell sharply.
Patients Social media advocacy: Healthcare professionals and the Trea... Social media is a hub of opinion, argument, and advocacy that traverses a virtually endless spectrum.
News Novo Nordisk leaps on new obesity drug data Shares in Novo Nordisk have risen sharply on new weight-loss data with an injectable formulation of new obesity candidate amycretin.
News Large study points to benefits - and risks - of GLP-1 drugs The largest observational study of GLP-1 weight-loss drugs suggests their benefits could be wide-ranging, but there are some risks to consider.
News High-dose semaglutide ramps up weight loss, says Novo Novo Nordisk's high-dose version of semaglutide boosts its weight-loss ability, but it still can't match its main rival in the obesity market.
News CEPI steps in to fund Moderna's pandemic flu jab Thanks to CEPI, Moderna's H5 bird flu vaccine can start a pivotal trial shelved after funding for the jab was pulled in the US by HHS Sec Kennedy.
Sales & Marketing Sponsored How to meet your physicians where they are online A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
